Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its ...

Future Market Insights provides reliable, data-driven insights that empower stakeholders to make informed decisions in the ...

A recent review published in Genes & Diseases by researchers from the Naval Medical University and the 922nd Hospital of the Joint Service Support Force of the PLA provides a comprehensive overview of ...

YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the ...

Two-day-old baby KJ Muldoon only had a few months left to live. Diagnosed with a rare and fatal genetic disease, his life hung in the balance — the only known treatment offering little hope of ...

A major breakthrough in cancer research has shown that using CRISPR gene editing technology to turn off a specific gene can help fight chemotherapy resistance in lung cancer. This discovery could open ...

Researchers have found a new way to reactivate fetal hemoglobin without the need for gene-editing therapy, according to a new study.

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

A Greer couple is hosting a fundraiser to support a costly gene editing procedure for their two children, who suffer from a ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds. On ...

Editas strengthened its balance sheet by raising $17.8 million through its ATM (at-the-market) offering in the third quarter ...